Acquisition by Pickering Grant of 57938 shares of Vaxcyte subject to Rule 16b-3
| PCVX Stock | USD 33.73 0.01 0.03% |
Slightly above 54% of Vaxcyte's investor base is interested to short. The analysis of overall sentiment of trading Vaxcyte stock suggests that many investors are impartial at this time. Vaxcyte's investing sentiment can be driven by a variety of factors including economic data, Vaxcyte's earnings reports, geopolitical events, and overall market trends.
Filed transaction by Vaxcyte Director, Officer Chief Executive Officer. Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
Vaxcyte Fundamental Analysis
We analyze Vaxcyte's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vaxcyte using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vaxcyte based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Book Value Per Share
Book Value Per Share Comparative Analysis
Vaxcyte is currently under evaluation in book value per share category among its peers. Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
Vaxcyte Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Vaxcyte stock to make a market-neutral strategy. Peer analysis of Vaxcyte could also be used in its relative valuation, which is a method of valuing Vaxcyte by comparing valuation metrics with similar companies.
Peers
Vaxcyte Related Equities
| REPL | Replimune | 10.68 | ||||
| UTHR | United Therapeutics | 4.16 | ||||
| RVMD | Revolution Medicines | 3.25 | ||||
| ORIC | Oric Pharmaceuticals | 2.57 | ||||
| ASND | Ascendis Pharma | 1.33 | ||||
| NUVL | Nuvalent | 0.34 | ||||
| ITOS | Iteos Therapeutics | 0.1 | ||||
| GBIO | Generation Bio | 0.44 | ||||
| RLAY | Relay Therapeutics | 3.29 | ||||
| VTYX | Ventyx Biosciences | 5.15 |
Additional Tools for Vaxcyte Stock Analysis
When running Vaxcyte's price analysis, check to measure Vaxcyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxcyte is operating at the current time. Most of Vaxcyte's value examination focuses on studying past and present price action to predict the probability of Vaxcyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxcyte's price. Additionally, you may evaluate how the addition of Vaxcyte to your portfolios can decrease your overall portfolio volatility.